Osimertinib administration as the primary epidermal growth factor receptor tyrosine kinase inhibitor therapy for brain metastasis of de Novo T790M-positive lung cancer

3Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

A 69-year-old woman underwent left upper lobectomy for left upper lobe lung adenocarcinoma. She later perceived a left visual field defect, and a brain metastasis was detected on head magnetic resonance imaging (MRI). Epidermal growth factor receptor (EGFR) testing identified two separate EGFR mutations: an L858R mutation in exon 21 and a de novo T790M mutation in exon 20. Treatment with osimertinib was started. After one month, head MRI showed that the brain metastasis had shrunk, and the visual field defect had also improved. In this case, first-line osimertinib was effective for treating brain metastasis of de novo T790Mpositive lung cancer.

References Powered by Scopus

Osimertinib or platinum-pemetrexed in EGFR T790M-Positive lung cancer

2820Citations
N/AReaders
Get full text

CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer

635Citations
N/AReaders
Get full text

Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer

443Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Efficacy of osimertinib against EGFRvIII+ glioblastoma

41Citations
N/AReaders
Get full text

Long-term response to osimertinib in elderly patients with lung adenocarcinoma harbouring de novo EGFR T790M: a case report and literature review

3Citations
N/AReaders
Get full text

High quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib

1Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Noguchi, S., Kawachi, H., Fukao, A., Terashita, S., Tajiri, T., Ikeue, T., … Sugita, T. (2019). Osimertinib administration as the primary epidermal growth factor receptor tyrosine kinase inhibitor therapy for brain metastasis of de Novo T790M-positive lung cancer. Internal Medicine, 58(20), 3029–3031. https://doi.org/10.2169/internalmedicine.3169-19

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 3

100%

Readers' Discipline

Tooltip

Agricultural and Biological Sciences 2

50%

Biochemistry, Genetics and Molecular Bi... 1

25%

Neuroscience 1

25%

Save time finding and organizing research with Mendeley

Sign up for free